超11亿美元,科弈药业全球首款纳米双抗ADC药物出海

MedTrend医趋势
Sep 03

9月2日,中国创新药企科弈药业(Novatim)宣布与美国Radiance Biopharma达成独家授权合作,将旗下“全球首款纳米双抗ADC药物”——KY-0301的海外开发、注册及商业化权益授予Radiance。Radiance Biopharma为此将支付1500万美元首付款,以及最高1.5亿美元的研发注册里程碑款和最高10亿美元的商业化里程碑款,同时还将依据授权区域年度净销售额获得递进式...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10